US 12,090,166 B2
Pharmaceutical composition for preventing or treating dentin-dental pulp disease or periodontal disease, containing LPAR2 inhibitor
Il Ho Jang, Yangsan-si (KR); Eun Jin Seo, Yangsan-si (KR); Jae Young Kim, Daegu (KR); Hyung Joon Kim, Yangsan-si (KR); Gabor J. Tigyi, Memphis, TN (US); Jung Hong Ha, Daegu (KR); and Da Sol Kim, Yangsan-si (KR)
Assigned to Stemden USA, LLC, Memphis, TN (US)
Appl. No. 17/059,198
Filed by PUSAN NATIONAL UNIVERSITY INDUSTRY-UNIVERSITY COOPERATION FOUNDATION, Busan (KR)
PCT Filed Aug. 9, 2019, PCT No. PCT/KR2019/010018
§ 371(c)(1), (2) Date Nov. 25, 2020,
PCT Pub. No. WO2020/032651, PCT Pub. Date Feb. 13, 2020.
Claims priority of application No. 10-2018-0092912 (KR), filed on Aug. 9, 2018; and application No. 10-2019-0096229 (KR), filed on Aug. 7, 2019.
Prior Publication US 2021/0196743 A1, Jul. 1, 2021
Int. Cl. C07H 21/04 (2006.01); A23L 33/13 (2016.01); A61K 31/713 (2006.01); A61P 1/02 (2006.01)
CPC A61K 31/713 (2013.01) [A23L 33/13 (2016.08); A61P 1/02 (2018.01)] 4 Claims
 
1. A method of treating dentin-dental pulp disease comprising:
administering a pharmaceutical composition comprising a LPAR2 (lysophosphatidic acid receptor 2) inhibitor, which is the following Chemical Formula 1 to a subject,

OG Complex Work Unit Chemistry
wherein the pharmaceutical composition promotes regeneration of hard tissues including dentin, bone and cementum or dental pulp tissues.